ClinicalTrials.gg

Program

Bimatoprost Ophthalmic Solution

Also written as “bimatoprost ophthalmic solution 0.03%”, “bimatoprost ophthalmic solution 0.01%” and “Bimatoprost ophthalmic solution 0.01% YSBP”.

Its studies are mostly in Glaucoma, Open-Angle · Hypotrichosis · Alopecia Areata, led by 3 companies.

Furthest: phase 4, since Nov 30, 20099 company-led studies, 2 open or runningNext primary completion: Nov 1, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie70 open or runningphase 4since Nov 30, 2009Nov 30, 2009none ahead
Amneal Pharmaceuticals11 open or runningphase 1since Feb 12, 2024Feb 12, 2024none ahead
YS Life Science11 open or runningphase 3since Jun 16, 2026Jun 16, 2026Nov 1, 2027phase 3 · NCT07661329

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 30, 2009First study: phase 4 study in Alopecia AreataNew to AbbVieAbbVie · NCT01023841 · 71 enrolled · United States, Brazil
  2. Feb 5, 2010Phase 2 study in Eyelash HypotrichosisAbbVie · NCT01064882 · 104 enrolled · United States
  3. Dec 2, 2010Phase 4 study in Glaucoma, Open-AngleAbbVie · NCT01253902 · 164 enrolled · United States, Canada
  4. Oct 6, 2011Phase 4 study in HypotrichosisAbbVie · NCT01448525 · 88 enrolled · United States
  5. Feb 10, 2012Phase 4 study in Glaucoma, Open-AngleAbbVie · NCT01547598 · 135 enrolled · Canada
  6. Jun 25, 2014Phase 4 study in Facial RhytidesAbbVie · NCT02176356 · 116 enrolled · United States
  7. May 2, 2016Phase 4 study in Glaucoma, Open-AngleAbbVie · NCT02863705 · 118 enrolled · Korea, Republic of
  8. Feb 12, 2024Amneal Pharmaceuticals’ first study: phase 1 study in Glaucoma, Open-AngleNew to Amneal PharmaceuticalsAmneal Pharmaceuticals · NCT06267274 · 240 planned · United States
  9. Jun 16, 2026YS Life Science’s first study: phase 3 study in Glaucoma, Open-AngleNew to YS Life ScienceYS Life Science · NCT07661329 · 600 planned · United States, India

Ahead

  1. Nov 1, 2027Primary completion: phase 3 study in Glaucoma, Open-AngleYS Life Science · NCT07661329

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07661329Glaucoma, Open-Angle · United States, India3RecruitingYS Life ScienceNov 1, 2027600
NCT06267274Glaucoma, Open-Angle · United States1RecruitingAmneal PharmaceuticalsMar 1, 2025240
NCT02863705Glaucoma, Open-Angle · Korea, Republic of4CompletedAbbVieJul 25, 2018118
NCT02176356Facial Rhytides · United States4CompletedAbbVieMay 3, 2015116
NCT01547598Glaucoma, Open-Angle · Canada4CompletedAbbVieJul 2013135
NCT01448525Hypotrichosis · United States4CompletedAbbVieApr 201288
NCT01253902Glaucoma, Open-Angle · United States, Canada4CompletedAbbVieOct 2011164
NCT01064882Eyelash Hypotrichosis · United States2CompletedAbbVieJul 2010104
NCT01023841Alopecia Areata · United States, Brazil4CompletedAbbVieNov 2, 201271

How it is read

Names in the registry

  • “bimatoprost ophthalmic solution 0.03%”, 4 entries
  • “bimatoprost ophthalmic solution 0.01%”, 2 entries
  • “Bimatoprost ophthalmic solution 0.01% YSBP”, 1 entry
  • “Bimatoprost Ophthalmic Solution, 0.01%”, 1 entry
  • “Bimatoprost ophthalmic solution 0.01%”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.